Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population.
- Author:
Xiao-Wei ZHANG
1
;
Zhen-Hua LIU
;
Xiao-Wei HU
;
Ye-Qing YUAN
;
Wen-Jun BAI
;
Xiao-Feng WANG
;
Huan SHEN
;
Yong-Ping ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Age of Onset; Aged; Anxiety; drug therapy; Depression; drug therapy; Hormone Replacement Therapy; Humans; Hypogonadism; blood; drug therapy; psychology; Male; Middle Aged; Quality of Life; Single-Blind Method; Testosterone; blood; deficiency; therapeutic use
- From: Chinese Medical Journal 2012;125(21):3806-3810
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDLate onset hypogonadism negatively impacts on men's psychological well-being. This study was conducted to examine the interrelationship among symptoms of testosterone deficiency, psychological well-being, and quality of life.
METHODSEligible subjects were randomized into active treatment and control groups, and were asked to complete the following questionnaires at baseline and month 6: aging male's symptoms (AMS) rating scale, hospital anxiety and depression scale (HADS), perceived stress scale (PSS) and the short form health survey-12 (SF-12). In this study, men were treated and monitored for 6 months with oral testosterone undecanoate (TU) capsules or vitamin E/C capsules in a single-blinded fashion. All in the active treatment group were administered a total of 120 - 160 mg TU orally on a daily basis. Total and free T levels between baseline and month 6 were compared.
RESULTSOne hundred and sixty eligible subjects were recruited and followed up. In the active treatment group, total serum testosterone concentrations before and after intervention were (7.98 ± 0.73) nmol/L and (13.7 ± 1.18) nmol/L. The mean HADS anxiety subscale scores for the subjects at baseline and at month 6 were 3.47 ± 0.4 and 1.72 ± 0.2, respectively (t = 1.526, P < 0.05). Additionally, the mean HADS depression subscale scores were 4.91 ± 0.6 and 2.39 ± 0.3, respectively (t = 3.466, P < 0.05). The mean scores on PSS for the subjects at baseline and at month 6 were 12.88 ± 2.1 and 9.83 ± 1.7, respectively (t = 4.009, P < 0.05). Significantly improved SF-12 could be observed (t = 1.433 and 1.118, respectively; both P < 0.05). No significant changes were observed in the control group at month 6.
CONCLUSIONAndrogen replacement not only improves androgen deficiency associated symptoms, but also enhances comprehensive improvement in psychological issues.